IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection
- 1 September 1992
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 14 (1) , 44-51
- https://doi.org/10.1002/ppul.1950140109
Abstract
Chronic bronchopulmonary infection with alginate‐producing, mucoid Pseudomonas aeruginosa is characteristically associated with cystic fibrosis (CF). A significant correlation between the antibody response to alginate and poor lung function has been reported. Enzyme‐linked immunosorbent assays were developed for the quantitation of human IgG1, IgG2, IgG3, and IgG4 antibodies to P. aeruginosa alginate. We investigated the pattern of IgG subclass antibodies against P. aeruginosa alginate in serum of patients with CF, others with chronic P. aeruginosa infection, and healthy controls. Healthy controls and patients with CF, before they acquired P. aeruginosa infection, had no or very low titers of antibodies against P. aeruginosa alginate. The latter with chronic infection had significantly higher antibody levels than all others groups, including patients with chronic P. aeruginosa infection but no CF. CF with chronic P. aeruginosa infection led to an inverse correlation between lung function parameters and levels of IgG3 and IgG4. Fifty‐seven patients with CF have been followed for an average of 12 years with multiple antibody assays covering the preinfection, early, and late stage of chronic infection. All of them developed IgG1 and IgG3 antibodies to alginate at the start of infection. IgG2 antibodies developed later and showed only a slow increase during the chronic infection. Patients who died had significantly higher IgG2 anti‐alginate antibody levels than other investigated groups. Elevated levels of IgG2 and IgG3 antibodies to P. aeruginosa alginate are a sign of poor prognosis in CF.Keywords
This publication has 30 references indexed in Scilit:
- Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.Thorax, 1990
- IgG subclass antibodies toPseudomonas aeruginosain sera from patients with chronicPs. aeruginosainfection investigated by ELISAClinical and Experimental Immunology, 1990
- Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.Journal of Clinical Investigation, 1989
- Increased IgG2 and IgG3 Concentration Is Associated with Advanced Pseudomonas Aeruginosa Infection and Poor Pulmonary Function in Cystic FibrosisActa Paediatrica, 1988
- Opsonophagocytic Killing Antibody toPseudomonas aeruginosaMucoid Exopolysaccharide in Older Noncolonized Patients with Cystic FibrosisNew England Journal of Medicine, 1987
- Recurrent Sinopulmonary Infection and Impaired Antibody Response to Bacterial Capsular Polysaccharide Antigen in Children with Selective IgG-Subclass DeficiencyNew England Journal of Medicine, 1985
- Studies on the Ability of Alginate to Act as a Protective Immunogen Against Infection with Pseudomonas aeruginosa in AnimalsThe Journal of Infectious Diseases, 1985
- Antiphagocytic effect of Pseudomonas aeruginosa exopolysaccharide.Journal of Clinical Pathology, 1980
- Ultracentrifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complementBiochemistry, 1976
- Purification of the galactose‐binding hemagglutinin of Pseudomonas aeruginosa by affinity column chromatography using sepharoseFEBS Letters, 1972